Key Highlights

  • Amylyx Pharmaceuticals' Phase 3 LUCIDITY trial for avexitide achieved its primary FDA-agreed endpoint in post-bariatric hypoglycemia.
  • The GLP-1 receptor antagonist delivered a 55% reduction in Level 2/3 hypoglycemic events compared to placebo.
  • The study also met all secondary goals.
  • The results pave the way for a year-end 2026 NDA filing for what could be the first approved PBH treatment.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced that its Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia achieved its primary FDA-agreed endpoint, with the GLP-1 receptor antagonist delivering a 55% reduction in Level 2/3 hypoglycemic events compared to placebo.

What Happened

The study also met all secondary goals, paving the way for a year-end 2026 NDA filing for what could become the first approved treatment for post-bariatric hypoglycemia.

Market Reaction

The disclosed information does not include stock price or trading data for Amylyx Pharmaceuticals following the trial results.

Outlook

The planned year-end 2026 NDA filing represents the next major disclosed milestone for avexitide, which would position the company to potentially deliver the first approved treatment specifically for post-bariatric hypoglycemia.